Dihexa (Oral) vs FGL
A side-by-side research comparison of Dihexa (Oral) and FGL across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dihexa (Oral) | FGL |
|---|---|---|
| Full name | Dihexa (N-hexanoic-Tyr-Ile-(6) Aminohexanoic Amide) | FGL (NCAM-Derived Peptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Activates hepatocyte growth factor (HGF) / c-Met receptor system in the brain, triggering dendritic spine formation, synaptogenesis, and neuronal survival. This creates new neural pathways for learning and memory. | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. |
| Molecular weight | 507.63 Da | ~1,800 Da |
| Half-life | ~12 hours | 4-8 hours |
| Bioavailability | ~70% oral, ~60% intranasal | Moderate (SubQ, partial BBB crossing) |
| Typical dose | 10-20 mg | 1-5 mg/kg (research) |
| Frequency | Daily or every other day | Daily or every other day |
| Route | Oral capsule or sublingual | Subcutaneous |
Dihexa (Oral) reported benefits
- Synaptogenesis (new brain connections)
- Dramatic memory enhancement
- Learning acceleration
- Neuroprotection
- Cognitive recovery after injury
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
Related comparisons
Research and educational reference only. Not medical advice.